**Supplemental Figures**

C:\Users\yin\Desktop\一修\一修草稿\supplemental fig\幻灯片1.TIF

**Supplemental Figure 1.** Relative circulating miR-320a expression level in patients treated with anthracycline combined chemotherapy measured by real-time PCR. Data are representative of three experiments, n=5. Data are expressed as mean ± SEM, \*P<0.05 versus control.

C:\Users\yin\Desktop\一修\一修草稿\supplemental fig.tif

**Supplemental Figure 2.** Effects of miR-320a on survival rate in doxorubicin (Doxo) treated mice. Survival was monitored for up to 14 days after a single dose of saline or doxorubicin was intraperitoneal injected to mice, n=20. \*P<0.05 versus control.

C:\Users\yin\Desktop\一修\一修草稿\sf3.tif **Supplemental Figure 3.** Circulating VEGFA level in mice with different treatments measured by ELISA. Data are expressed as mean ± SEM, n≥5.

G:\一修\一修草稿\supplemental fig4.tif

**Supplemental Figure 4.** Doxorubicin (Doxo) disturbed the cardiac vascular homeostasis by regulating miR-320a-VEGFA signal pathway.